Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 21, 2013

Primary Completion Date

August 1, 2018

Study Completion Date

August 1, 2018

Conditions

Acinar Cell Adenocarcinoma of the PancreasDuct Cell Adenocarcinoma of the PancreasRecurrent Pancreatic CancerStage IV Pancreatic Cancer

Interventions

DRUG

metformin hydrochloride

Given PO

DRUG

oxaliplatin

Given IV

DRUG

leucovorin calcium

Given IV

DRUG

fluorouracil

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (2)

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland

Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors

lead

Case Comprehensive Cancer Center

OTHER

NCT01666730 - Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter